Effect of glucagon-like peptide-1 analogue combined with insulin for treating obese or overweight type 2 diabetes
10.3760/cma.j.issn.1008-6706.2012.18.004
- VernacularTitle:利拉鲁肽联合胰岛素治疗肥胖或超重的2型糖尿病患者疗效观察
- Author:
Hongli LIU
;
Yeju WANG
;
Jianning HAO
;
Yijia LI
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 2;
Glucagon-like peptide-1 analogue;
Isulin;
Obesity
- From:
Chinese Journal of Primary Medicine and Pharmacy
2012;19(18):2727-2728
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the therapeutic efficacy and safety of the glucagon-like peptide-1 ( GLP-1 )analogue combined with isulin for treating obese or overweight type 2 diabetes.Methods 40 cases with obese or overweight type 2 diabetic patients( body mass index(BMI) ≥24) who have previously used human insulin,and experienced poor glycemic control( ≥7.5％ ) were selected.They were randomly divided into two groups.A group treated by GLP-1 analogue liraglutide plus insulin,and B group by continuous adjustment of insulin.12 weeks later,fasting blood glucose(FBG),2-hour plasma glucose (2hPG),hemoglobin A 1 C (HbA1c),body weight were observed and the incidence of hypoglycemia,insulin dosage were recorded.Results Weight and insulin dosage of group A was significantly lower than those of group B after treatment 12 week( t =2.738,2.865,all P ＜ 0.01 ).Numbers of hypoglycemia events were 6 in group A(30％ ),and 9 in group B(45％ ),but there was no statistical significance between the two groups ( P ＞ 0.05).Conclusion The addition of liraglutide to insulin in patients with obese or overweight type 2 diabetes is associated with reductions in weight and insulin dosage,without increase risk of hypoglycemia.This treatment proved effective and safe.
